Google Search
A well-documented Business Plan aids in business funding and it is proven to help businesses grow by 30% faster.
Test Your Business ideas- We clear your doubts on Business concept and validate it properly. Often Businesses fail when the Business Plan is weak.
Market Research & High Industry Demand- We will analyse the Market Potential for optimal Industry Growth.
- Overview
- Stats
- Introduction
- Information
- Contact Us
- Project At A Glance
- Profitability And Net Cash Accruals
- Cost Of Project
- Asssessement Of Working Capital Requirements
- Profitability Ratios, Dscr, Debt Equity
- Break Even Analysis
- Means Of Finance
- Projected Balance Sheet
- Repayment Of Term Loan
- Debt Service Coverage Ratio
- Depreciation Chart
- Projected Pay-Back Period
- Projected Irr
- Company Summary
- Reasons For Buying The Report
- Our Approach
- Table Of Content
- Financial Plan
- Information/ Disclaimer
Manufacturing of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol).
Production of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol). Investment Opportunities in Pharmaceutical Industry. An active ingredient (AI) is that the ingredient in an exceedingly pharmaceutical drug that's biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active i.e. bulk medicine are utilized in medicine, and therefore the term active substance could also be used for natural products. Thus, depending on the drug’s administered dosage, the reactions and results differ. Certain drugs are comprised of more than one kind of API. Amoxicillin is an antibiotic used to treat variety of bacterial infections. These include middle ear infection, strep throat, pneumonia, skin infections, and tract infections among others. It’s taken orally, or less usually by injection. Active Pharmaceutical Ingredient (API), is that the term used to check with the biologically active component of a drug product (e.g. tablet, capsule). Drug products are typically composed of many elements. The aforementioned API is that the primary ingredient. Alternative ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components utilized in the drug is known as "formulation." Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and bound alternative intestinal infections it also can be used for variety of sexually transmitted infections, as well as chlamydia and gonorrhea infections. At the side of alternative medications, it's going to even be used for malaria. It may be taken by mouth or intravenously with doses once per day. It is on the world Health Organization's List of Essential Medicines, the safest and most effective medicines required in a very health system. It’s one in all the most usually prescribed antibiotics in children. Trim ox is on the market as a generic medication. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Azithromycin alone and in combination with different medications is currently being studied for the treatment of coronavirus wellness 2019 (COVID-19). Currently, azithromycin has been used with hydroxychloroquine to treat certain patients with COVID-19. However, there are mixed reports of effectiveness once azithromycin was used at the side of alternative medications to treat other viral respiratory infections. Azithromycin also has been used to treat bacterial infections in hospitalized patients with COVID-19. A lot of information is required before any conclusions may be made regarding the possible advantages and risks of using azithromycin either alone or together with hydroxychloroquine in patients with COVID-19. Amoxicillin Trihydrate may be a hydrate that's the Trihydrate type of amoxicillin; a semisynthetic antibiotic, used either alone or together with potassium clavulanate (under the name Augmentin) for treatment of a variety of bacterial infections. It’s a role as an antibacterial drug and an antimicrobial agent. It contains an amoxicillin. Manufacturing Process The manufacturing process of Paracetamol is summarized in the following steps: -charge acetic acid to the reactor. -add p-nitro phenol as a starting material and iron powder as catalyst. -Heat to temp 80-90 ºC. -The reaction is exothermic and temp will rise to 130 ºC. -After slight cooling -Reflux the reaction at 118ºC for 3-4 hours. -Cool to 60 ºC. -Add methanol to the reaction. -Reflux for 1 hour. -distill the methanol and recycle. -Add water to the obtained cake. -And make a solution -Add activated carbon. -Filter -Dry the cake. -Pulverize the dry cake to get the Paracetamol fine powder. Applications:- Communicable Diseases Oncology Diabetes Cardiovascular Diseases Pain Management Respiratory Diseases Other Therapeutic Applications Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredient Market is valued at USD 172.69 Billion in 2018 and expected to reach USD 263.80 Billion by 2025 with the CAGR of 6.24% over the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Drugs and over-the-counter (OTC) drugs. In 2019, the prescribed drugs segment is expected to account for the most important share of the APIs market. The demand for drugs falling under this class has increased significantly in recent years because of the rising prevalence of target diseases. Additionally, the most important share of the prescription drugs segment also can be attributed to the increased focus of innovator corporations on the development of specialty drugs and affordability of health care. The implementation of significant federal reforms to improve the affordability of healthcare, especially in the, us has expanded the consumption of each traditional and specialty medicine. Also, inflation has played a key role in enhancing revenue from the sales of prescription drugs, significantly specialty drugs. All these factors are collectively responsible for the large share of this phase. Based on the kind of drug, the APIs market can be classified into two segments prescribed. Manufacturer Insights On the basis of type of manufacturer, the API market has been segmented into merchant and captive APIs. Captive API command the most important share in 2019 because of simple availability of raw materials and intensive capitalization of major key players for the development of high-end manufacturing facilities. API is calculable to be the fastest-growing segment over the forecast period. The segment growth is driven by factors similar to high cost of in-house manufacturing of those molecules and rising demand for biopharmaceuticals. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs Active Pharmaceutical Ingredient (APIs) are portions of any drugs that are biologically active in nature. The APIs have significant use in the manufacturing of effective and safe medicines. Depending on the drug’s administered dosage, the reactions and results take issue according to the requirement and use for specific treatment of diseases. Sure medicine are contained of over one kind of API. medicine are chosen primarily for his or her active ingredients to treat variety of chronic and infectious diseases similar to diabetes, cancer, arthritis, bone & joint infections, pneumonia, otitis, streptococcal pharyngitis, cellulites, and tract infections. However, the standard will vary widely from one whole to a different. Medicine are chosen primarily from active ingredients within the liquid or solid form like tablet or alternative throughout. Global Active Pharmaceutical Ingredient Market Dynamics The key issue for growth of worldwide Active Pharmaceutical Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has up to 18.1 million new cases as well as 9.6 million deaths across the world. Because of such rise within the cases of cancer, the new drugs discovery using the Active Pharmaceutical Ingredient has become essential. Recently in line with the American Chemical Society in 2019, there has been 48 new drugs has been approved by the fad U.S. out of that 11 for new cancer treatments with the innovative molecular pharmaceutical ingredients. However, the Active Pharmaceutical Ingredient market is hampered by would like for prime investment with huge capital demand for research and developments. Moreover rising health cautiousness among the people with technological advancement immense investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional growth can provide huge opportunity for Active Pharmaceutical Ingredient market. For instance in 2019, Raquel has been acquired by Merck & Co. for roughly around USD 2.7 billion in cash, for making cancer drug using Active Pharmaceutical Ingredient with the most recent small-molecule-focused. Expansion of Manufacturing Facilities Creating Lucrative Opportunities for Market Growth Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Focus on healthcare to drive the active pharmaceutical ingredients market The spending on healthcare has grown at a rapid pace in recent years and it increased at a CAGR of 6.92% between the years 2003 and 2013. The healthcare spending growth was significantly higher than the population growth rate that grew at a CAGR of 1.22% for the same period. The per capita healthcare spending rose from just under US$ 600 in 2003 to above US$ 1000 in 2013, at an average CAGR of 5.62%. The focus on healthcare spending was observed to be a global phenomenon and this directly benefited the active pharmaceutical ingredients market. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Production of Paracetamol (Acetaminophen), bulk pharmaceutical active ingredient Investment Opportunities in APIs KSMs Drug Intermediates Bulk Drug Industries Manufacturing Business Ideas in Pharmaceutical Industry Key Players Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK). Sun Pharmaceutical Industries Ltd. Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
| Plant capacity | Plant & machinery | Working capital | Cost of Project | T.C.I | Return | Break even |
|---|---|---|---|---|---|---|
| - | - | - | - | 1% | 0% |
Introduction
We can provide you detailed project reports on the following topics. Please select the projects of your interests.
Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.
We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.
Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.
- One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
- One Crore is equivalent to ten million (10,000,000)
- T.C.I is Total Capital Investment
- We can modify the project capacity and project cost as per your requirement.
- We can also prepare project report on any subject as per your requirement.
- Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.
| COST OF PROJECT | MEANS OF FINANCE | ||||||
|---|---|---|---|---|---|---|---|
| Particulars | Existing | Proposed | Total | Particulars | Existing | Proposed | Total |
| Land & Site Development Exp. | ********** | ********** | ********** | Capital | ********** | ********** | ********** |
| Buildings | ********** | ********** | ********** | Share Premium | ********** | ********** | ********** |
| Plant & Machineries | ********** | ********** | ********** | Other Type Share Capital | ********** | ********** | ********** |
| Motor Vehicles | ********** | ********** | ********** | Reserves & Surplus | ********** | ********** | ********** |
| Office Automation Equipments | ********** | ********** | ********** | Cash Subsidy | ********** | ********** | ********** |
| Technical Knowhow Fees & Exp. | ********** | ********** | ********** | Internal Cash Accruals | ********** | ********** | ********** |
| Franchise & Other Deposits | ********** | ********** | ********** | Long/Medium Term Borrowings | ********** | ********** | ********** |
| Preliminary & Pre-operative Exp | ********** | ********** | ********** | Debentures / Bonds | ********** | ********** | ********** |
| Provision for Contingencies | ********** | ********** | ********** | Unsecured Loans/Deposits | ********** | ********** | ********** |
| Margin Money - Working Capital | ********** | ********** | ********** | ********** | ********** | ********** | ********** |
| Total | ********** | ********** | ********** | Total | ********** | ********** | ********** |
| PARTICULARS | OPERATING YEARS | ||||
|---|---|---|---|---|---|
| 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | |
| ********** | ********** | ********** | ********** | ********** | |
| Revenue/Income/Realisation | ********** | ********** | ********** | ********** | ********** |
| Gross Sales Realisation | ********** | ********** | ********** | ********** | ********** |
| Less : Excise Duties/Levies | ********** | ********** | ********** | ********** | ********** |
| Net Sales Realisation | ********** | ********** | ********** | ********** | ********** |
| Total Revenue/Income/Realisation | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | |
| Expenses/Cost of Products/Services/Items | ********** | ********** | ********** | ********** | ********** |
| Raw Material Cost | ********** | ********** | ********** | ********** | ********** |
| Indigenous | ********** | ********** | ********** | ********** | ********** |
| Total Nett Consumption | ********** | ********** | ********** | ********** | ********** |
| Lab & ETP Chemical Cost | ********** | ********** | ********** | ********** | ********** |
| Packing Material Cost | ********** | ********** | ********** | ********** | ********** |
| Sub Total of Net Consumption | ********** | ********** | ********** | ********** | ********** |
| Miscellaneous Cost | ********** | ********** | ********** | ********** | ********** |
| Employees Expenses | ********** | ********** | ********** | ********** | ********** |
| Fuel Expenses | ********** | ********** | ********** | ********** | ********** |
| Power/Electricity Expenses | ********** | ********** | ********** | ********** | ********** |
| Depreciation | ********** | ********** | ********** | ********** | ********** |
| Royalty & Other Charges | ********** | ********** | ********** | ********** | ********** |
| Repairs & Maintenance Exp. | ********** | ********** | ********** | ********** | ********** |
| Other Mfg. Expenses | ********** | ********** | ********** | ********** | ********** |
| Cost of Output of Goods Sold | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | |
| Gross Profit | ********** | ********** | ********** | ********** | ********** |
| Administration Expenses | ********** | ********** | ********** | ********** | ********** |
| Technical Knowhow Fees & Exp. | ********** | ********** | ********** | ********** | ********** |
| Financial Charges | ********** | ********** | ********** | ********** | ********** |
| Long/Medium Term Borrowing | ********** | ********** | ********** | ********** | ********** |
| On Wkg. Capital Borrowings | ********** | ********** | ********** | ********** | ********** |
| Total Financial Charges | ********** | ********** | ********** | ********** | ********** |
| Selling Expenses | ********** | ********** | ********** | ********** | ********** |
| Total Cost of Sales | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | |
| Net Profit Before Taxes | ********** | ********** | ********** | ********** | ********** |
| Tax on Profit | ********** | ********** | ********** | ********** | ********** |
| Net Profit After Taxes | ********** | ********** | ********** | ********** | ********** |
| Depreciation Added Back | ********** | ********** | ********** | ********** | ********** |
| Technical Knowhow Fees & Exp. | ********** | ********** | ********** | ********** | ********** |
| Net Cash Accruals | ********** | ********** | ********** | ********** | ********** |
| PARTICULARS | EXISTING | PROPOSED | TOTAL |
|---|---|---|---|
| COST OF PROJECT | |||
| Land & Site Development Exp. | |||
| Land Area Required | ********** | ********** | ********** |
| Land Development Cost, Boundary Wall, Gate & Road etc. | ********** | ********** | ********** |
| ********** | ********** | ********** | |
| Buildings | ********** | ********** | ********** |
| Factory Building - | ********** | ********** | ********** |
| Office Buildings | ********** | ********** | ********** |
| ********** | ********** | ********** | |
| Plant & Machineries | ********** | ********** | ********** |
| Indigenous Machineries | ********** | ********** | ********** |
| Erection & Installation | ********** | ********** | ********** |
| Laboratory Equipments | ********** | ********** | ********** |
| Miscellaneous Equipments like pumps, valves, pipeline & fittings | ********** | ********** | ********** |
| Imported Machineries | ********** | ********** | ********** |
| Technical know how | ********** | ********** | ********** |
| ********** | ********** | ********** | |
| Office Vehicles | ********** | ********** | ********** |
| Office Automation Equipments (Telephone/ Fax/ Computer) | ********** | ********** | ********** |
| Office Equipment, Furniture plus Other Equipment & Accessories | ********** | ********** | ********** |
| Other Misc. Assets | ********** | ********** | ********** |
| ********** | ********** | ********** | |
| Pre-operative & Preliminary Expenses | ********** | ********** | ********** |
| Provision for Contingencies | ********** | ********** | ********** |
| ********** | ********** | ********** | |
| Total Capital Cost of Project | ********** | ********** | ********** |
| Margin Money for Working Capital | ********** | ********** | ********** |
| Total Cost of Project | ********** | ********** | ********** |
| PARTICULARS | STK.PRD. | STK.PRD. | OPERATING YEARS | |||||
|---|---|---|---|---|---|---|---|---|
| 1st Year | 2nd Yr &+ | 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | ||
| Capacity | Months | Months | % | ********** | ********** | ********** | ********** | ********** |
| CURRENT ASSETS | ********** | ********** | ********** | ********** | ********** | |||
| Stocks on Hand | ********** | ********** | ********** | ********** | ********** | |||
| Raw Material Cost | ********** | ********** | ********** | ********** | ********** | |||
| Indigenous | ********** | ********** | M | ********** | ********** | ********** | ********** | ********** |
| Lab & ETP Chemical | ********** | ********** | M | ********** | ********** | ********** | ********** | ********** |
| Packing Material | ********** | ********** | M | ********** | ********** | ********** | ********** | ********** |
| Consumable Store | ********** | ********** | M | ********** | ********** | ********** | ********** | ********** |
| Work-in-Process | ********** | ********** | D | ********** | ********** | ********** | ********** | ********** |
| Finished Goods | ********** | ********** | M | ********** | ********** | ********** | ********** | ********** |
| Current Expenses | ********** | ********** | M | ********** | ********** | ********** | ********** | ********** |
| Receivables | ********** | ********** | M | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | ||
| Total | ********** | ********** | ********** | ********** | ********** | |||
| Cash/Bank Balances | ********** | ********** | ********** | ********** | ********** | |||
| Gross Wkg. Capital | ********** | ********** | ********** | ********** | ********** | |||
| PARTICULARS | OPERATING YEARS | |||||
|---|---|---|---|---|---|---|
| 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | ||
| Profit Percentages to Net Sales | ||||||
| Gross Profit | ********** | ********** | ********** | ********** | ********** | |
| % Of G.P. to Net Sales | ********** | ********** | ********** | ********** | ********** | |
| Net Profit Before Taxes | ********** | ********** | ********** | ********** | ********** | |
| % of N.P.B.T. To Net Sales | ********** | ********** | ********** | ********** | ********** | |
| Net Profit After Taxes | ********** | ********** | ********** | ********** | ********** | |
| % of N.P.A.T. To Net Sales | ********** | ********** | ********** | ********** | ********** | |
| Debt Service Coverage Ratio | ********** | ********** | ********** | ********** | ********** | |
| Debt Service Coverage Ratio | ||||||
| Funds Available to Service Debts | ||||||
| Net Profit After Taxes | ********** | ********** | ********** | ********** | ********** | |
| Depreciation Charges | ********** | ********** | ********** | ********** | ********** | |
| Technical Knowhow Fees & Exp | ********** | ********** | ********** | ********** | ********** | |
| Interest on Long/Medium Term | ********** | ********** | ********** | ********** | ********** | |
| Total | ********** | ********** | ********** | ********** | ********** | |
| Debt Service Obligations | ||||||
| Repayment of Long/Medium Term | ********** | ********** | ********** | ********** | ********** | |
| Interest on Long/Medium Term | ********** | ********** | ********** | ********** | ********** | |
| Total | ********** | ********** | ********** | ********** | ********** | |
| ********** | ********** | ********** | ********** | ********** | ||
| D. S. C. R. (Individual) | ********** | ********** | ********** | ********** | ********** | |
| D. S. C. R. (Cumulative) | ********** | ********** | ********** | ********** | ********** | |
| D. S. C. R. (Overall) | ********** | ********** | ********** | ********** | ********** | |
| Parameters | ||||||
| Initial Equity Capital | ********** | ********** | ********** | ********** | ********** | ********** |
| Credit Balance in P & L | ********** | ********** | ********** | ********** | ********** | ********** |
| Total Capital exclUnsec Deposits | ********** | ********** | ********** | ********** | ********** | ********** |
| Unsecured Dep. | ********** | ********** | ********** | ********** | ********** | ********** |
| Total Equity incl Unsecured Deposits | ********** | ********** | ********** | ********** | ********** | ********** |
| Long/Medium Term Borrowings from Bank | ********** | ********** | ********** | ********** | ********** | ********** |
| Term lia. Incl Unsecured Deposit | ********** | ********** | ********** | ********** | ********** | ********** |
| Total Liabilities | ********** | ********** | ********** | ********** | ********** | ********** |
| Total Liabilities incl Unsecured Deposits | ********** | ********** | ********** | ********** | ********** | ********** |
| DEBT EQUITY RATIO considering | ********** | ********** | ********** | ********** | ********** | ********** |
| DEBT EQUITY RATIO considering | ||||||
| I.E.Total Term Lia./NW | ||||||
| Unsecured Dep. as Equity | ********** | ********** | ********** | ********** | ********** | ********** |
| Unsecured Dep. as Debt | ********** | ********** | ********** | ********** | ********** | ********** |
| Total Outside Lia./NW | ********** | ********** | ********** | ********** | ********** | ********** |
| Total Outside Lia./NW | ********** | ********** | ********** | ********** | ********** | |
| Assets Turnover Ratio (x) | ********** | ********** | ********** | ********** | ********** | |
| No. of Shares of 10.00 each | ********** | ********** | ********** | ********** | ********** | |
| Earnings Per Share (EPS) (in) | ********** | ********** | ********** | ********** | ********** | |
| Proposed divident | ********** | ********** | ********** | ********** | ********** | |
| Cash EPS (in) | ********** | ********** | ********** | ********** | ********** | |
| Dividend Per Share(DPS) (in) | ********** | ********** | ********** | ********** | ********** | |
| Payout Ratio (%Age) | ********** | ********** | ********** | ********** | ********** | |
| Retained Earnings/Share (in) | ********** | ********** | ********** | ********** | ********** | |
| Retained Earnings (%Age) | ********** | ********** | ********** | ********** | ********** | |
| Book Value Per Share (in) | ********** | ********** | ********** | ********** | ********** | |
| Debt Per Share (in) | ********** | ********** | ********** | ********** | ********** | |
| Probable Mkt. Price/Share(in) | ********** | ********** | ********** | ********** | ********** | |
| Price / Book Value (x) | ********** | ********** | ********** | ********** | ********** | |
| Price Earnings Ratio (x) | ********** | ********** | ********** | ********** | ********** | |
| Yield (%Age) | ********** | ********** | ********** | ********** | ********** | |
| PARTICULARS | OPERATING YEARS | |||||
|---|---|---|---|---|---|---|
| Ratio | 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | |
| BREAK EVEN ANALYSIS | ||||||
| Total Value of Output | ********** | ********** | ********** | ********** | ********** | |
| Variable Cost & Expenses | ||||||
| Raw Material Cost | ********** | ********** | ********** | ********** | ********** | ********** |
| Lab & ETP Chemical Cost | ********** | ********** | ********** | ********** | ********** | ********** |
| Packing Material Cost | ********** | ********** | ********** | ********** | ********** | ********** |
| Sales Commission/Exp. | ********** | ********** | ********** | ********** | ********** | ********** |
| Sub-total | ********** | ********** | ********** | ********** | ********** | |
| Less: W.I.P. Adjustments | ********** | ********** | ********** | ********** | ********** | |
| Total Variable Cost | ********** | ********** | ********** | ********** | ********** | |
| Net Contribution | ********** | ********** | ********** | ********** | ********** | |
| Profit Volume Ratio (%) | ********** | ********** | ********** | ********** | ********** | |
| Semi-Var./Semi-Fixed Exp. | ********** | ********** | ********** | ********** | ********** | ********** |
| Miscellaneous Cost | ********** | ********** | ********** | ********** | ********** | ********** |
| Employees Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Power/Electricity Expen | ********** | ********** | ********** | ********** | ********** | ********** |
| Fuel Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Royalty & Other Charges | ********** | ********** | ********** | ********** | ********** | ********** |
| Repairs & Maintenance E | ********** | ********** | ********** | ********** | ********** | ********** |
| Other Mfg. Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Administration Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Selling Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Interest on Wkg.Capital | ********** | ********** | ********** | ********** | ********** | ********** |
| Tot.Semi-Var./Fixed Exp. | ********** | ********** | ********** | ********** | ********** | ********** |
| Fixed Expenses / Cost | ********** | ********** | ********** | ********** | ********** | ********** |
| Miscellaneous Cost | ********** | ********** | ********** | ********** | ********** | ********** |
| Employees Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Power/Electricity Expen | ********** | ********** | ********** | ********** | ********** | ********** |
| Fuel Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Royalty & Other Charges | ********** | ********** | ********** | ********** | ********** | ********** |
| Repairs & Maintenance E | ********** | ********** | ********** | ********** | ********** | ********** |
| Other Mfg. Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Administration Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Selling Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Intrest-Fixed Borrowing | ********** | ********** | ********** | ********** | ********** | ********** |
| Intrest-Working Capital | ********** | ********** | ********** | ********** | ********** | ********** |
| Depreciation Charges | ********** | ********** | ********** | ********** | ********** | ********** |
| Deferred Expenses W/Off | ********** | ********** | ********** | ********** | ********** | ********** |
| Total Fixed Expenses | ********** | ********** | ********** | ********** | ********** | ********** |
| Tot.Fixed/Semi-Fixed Exp | ********** | ********** | ********** | ********** | ********** | ********** |
| Tot.Cash Fixed/SemiFixed | ********** | ********** | ********** | ********** | ********** | ********** |
| Cash Break Even Sales | ********** | ********** | ********** | ********** | ********** | ********** |
| Cash Margin of Safety | ********** | ********** | ********** | ********** | ********** | ********** |
| Break Even Sales | ********** | ********** | ********** | ********** | ********** | ********** |
| Margin of safety | ********** | ********** | ********** | ********** | ********** | ********** |
| At Maximum Utilisation : | Year | ********** | ********** | ********** | ********** | ********** |
| (as % of Installed Capacity) | ||||||
| Cash B.E.P. : | % | xx% | xx% | xx% | xx% | xx% |
| B.E.P. : | % | xx% | xx% | xx% | xx% | xx% |
| MEANS OF FINANCE | |||
|---|---|---|---|
| Equity Share Capital | ********** | ********** | ********** |
| Others - Preference Share Capital | ********** | ********** | ********** |
| Total Equity Share Capital | ********** | ********** | ********** |
| ********** | ********** | ********** | |
| Long/Medium Term Borrowings | ********** | ********** | ********** |
| FROM BANK | ********** | ********** | ********** |
| From Other Financial Institutions | ********** | ********** | ********** |
| Total Long/Medium Term Borrowings | ********** | ********** | ********** |
| ********** | ********** | ********** | |
| Total Means of Finance | ********** | ********** | ********** |
| PARTICULARS | OPERATING YEARS | ||||
|---|---|---|---|---|---|
| 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | |
| Equity Share Capital | ********** | ********** | ********** | ********** | ********** |
| Surplus of Previous Year | ********** | ********** | ********** | ********** | ********** |
| Add : Net Profit After Taxes | ********** | ********** | ********** | ********** | ********** |
| Surplus at the End of Year | ********** | ********** | ********** | ********** | ********** |
| Unsecured Deposits | ********** | ********** | ********** | ********** | ********** |
| Long/Medium Term Borrowings Proposed-FROM BANK | ********** | ********** | ********** | ********** | ********** |
| Bank Borrowing for Wkg. Capital | ********** | ********** | ********** | ********** | ********** |
| Current Liabilities | ********** | ********** | ********** | ********** | ********** |
| Sundry Creditors | ********** | ********** | ********** | ********** | ********** |
| Other Current Liabilities | ********** | ********** | ********** | ********** | ********** |
| Total Current Liabilities | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | |
| Total of Liabilities | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | |
| ASSETS | ********** | ********** | ********** | ********** | ********** |
| Fixed Assets | ********** | ********** | ********** | ********** | ********** |
| Gross Block | ********** | ********** | ********** | ********** | ********** |
| Less : Depreciation to Date | ********** | ********** | ********** | ********** | ********** |
| Net Block | ********** | ********** | ********** | ********** | ********** |
| Current Assets | ********** | ********** | ********** | ********** | ********** |
| Stocks on Hand | ********** | ********** | ********** | ********** | ********** |
| Receivables | ********** | ********** | ********** | ********** | ********** |
| Other Current Assets | ********** | ********** | ********** | ********** | ********** |
| Cash and Bank Balances | ********** | ********** | ********** | ********** | ********** |
| Total Current Assets | ********** | ********** | ********** | ********** | ********** |
| P & P Exp. and/or Other Dvp.Exp. | ********** | ********** | ********** | ********** | ********** |
| (To The Extent Not W/Off) | ********** | ********** | ********** | ********** | ********** |
| Other Non Current Assets | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | |
| Total of Assets | ********** | ********** | ********** | ********** | ********** |
| ROI (Average of Fixed Assets) | ********** | ********** | ********** | ********** | ********** |
| RONW (Average of Share Capital) | ********** | ********** | ********** | ********** | ********** |
| ROI (Average of Total Assets) | ********** | ********** | ********** | ********** | ********** |
INTEREST AND REPAYMENT ON TERM LOANS
| A | Name of Institution-Bank | ABC BANK | |
|---|---|---|---|
| B | Term Borrowing Amount | ********** | xx |
| C | Repayment Term (Years) | ********** | Years |
| D | Repayment Instalments | ********** | Instalments |
| E | Repayment Commencement | Year - 0; 3rd Qtr. | |
| F | Rate of Interest(General) | xxxx% | p.a. |
| G | Rate of Interest(Initial) | 0.00% | p.a. |
| H | Apply Gen. Int. Rate from Year | x Quarter :: x | |
| I | Interest Calculation | Quarterly |
| Debt Service Coverage Ratio | ||||||
|---|---|---|---|---|---|---|
| Funds Available to Service Debts | ||||||
| Net Profit After Taxes | ********** | ********** | ********** | ********** | ********** | |
| Depreciation Charges | ********** | ********** | ********** | ********** | ********** | |
| Technical Knowhow Fees & Expenses | ********** | ********** | ********** | ********** | ********** | |
| Interest on Long/Medium Term | ********** | ********** | ********** | ********** | ********** | |
| Total | ********** | ********** | ********** | ********** | ********** | |
| Debt Service Obligations | ********** | ********** | ********** | ********** | ********** | |
| Repayment of Long/Medium Term | ********** | ********** | ********** | ********** | ********** | |
| Interest on Long/Medium Term | ********** | ********** | ********** | ********** | ********** | |
| Total | ********** | ********** | ********** | ********** | ********** | |
| ********** | ********** | ********** | ********** | ********** | ||
| D. S. C. R. (Individual) | ********** | ********** | ********** | ********** | ********** | |
| D. S. C. R. (Cumulative) ..... | ********** | ********** | ********** | ********** | ********** | |
| D. S. C. R. (Overall) ........ | ********** | ********** | ********** | ********** | ********** |
DEPRECIATION CHARGES AS PER BOOKS (TOTAL)
| Operating Year | F.Assets Type A-1 | F.Assets Type A-2 | F.Assets Type B | F.Assets Type C | F.Assets Type D-1 | F.Assets Type D-2 | Total |
|---|---|---|---|---|---|---|---|
| Particulars | Factory Building | Office Buildings | Plant & Machinery | Office Vehicles | Office Automation Equipments (Telephone/ Fax/ Computer) | Furniture & Fixtures | |
| 1-2 | ********** | ********** | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| 2-3 | ********** | ********** | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| 3-4 | ********** | ********** | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| 4-5 | ********** | ********** | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| 5-6 | ********** | ********** | ********** | ********** | ********** | ********** | ********** |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** | |
| ********** | ********** | ********** | ********** | ********** | ********** | ********** |
| Particulars | Method | Deprn.Rate | Part Consideration (for Asset put to use less than xx months) |
|---|---|---|---|
| Type A :: Buildings | |||
| Factory Building - | WDV | ********** | ********** |
| Office Buildings | WDV | ********** | ********** |
| Type C | |||
| Office Vehicles | WDV | ********** | ********** |
| Type D :: Misc. Fixed Assets | |||
| Office Automation Equipments (Telephone/ Fax/ Computer) | WDV | ********** | ********** |
| Furniture & Fixtures | WDV | ********** | ********** |
| Type B :: Plant & Machineries |
| Projected Pay Back Period | |||||
|---|---|---|---|---|---|
| Particulars | Operating Years | ||||
| 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | |
| Year | 1 | 2 | 3 | 4 | 5 |
| Initial Investment | ********* | ||||
| Total Initial Investment | ********* | ||||
| Yearly Cash Flow | ********* | ********* | ********* | ********* | ********* |
| Accumulated Cash Flow | ********* | ********* | ********* | ********* | ********* |
| Accumulated Cash Flow | ********* | ********* | ********* | ********* | ********* |
| Pay Back Period | xx Years xx Months | xx Years xx months | |||
| Projected IRR | |||||
|---|---|---|---|---|---|
| Year | CFAT | PV factor @**% | ********* | ||
| Initial Investment | ********* | ********* | ********* | ||
| 1-2 | ********* | ********* | ********* | ||
| 2-3 | ********* | ********* | ********* | ||
| 3-4 | ********* | ********* | ********* | ||
| 4-5 | ********* | ********* | ********* | ||
| 5-6 | ********* | ********* | ********* | ||
| Total PV | ********* | ********* | |||
| IRR | ********* | ********* | |||
NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.
Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.
NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.
- This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, demand of the product and reasons for investing in the product.
- This report provides vital information on the product like its definition, characteristics and segmentation.
- This report helps you market and place the product correctly by identifying the target customer group of the product.
- This report helps you understand the viability of the project by disclosing details like raw materials required, manufacturing process, project costs and snapshot of other project financials.
- The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decision.
- Our research reports broadly cover Indian markets, present analysis, outlook and forecast.
- The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players.
- We use reliable sources of information and databases. And information from such sources is processed by us and included in the report.
Introduction
- Project Introduction
- Project Objective and Strategy
- Concise History of the Product
- Properties
- BIS (Bureau of Indian Standards) Provision & Specification
- Uses & Applications
Market Study and Assessment
- Current Indian Market Scenario
- Present Market Demand and Supply
- Estimated Future Market Demand and Forecast
- Statistics of Import & Export
- Names & Addresses of Existing Units (Present Players)
- Market Opportunity
Raw Material
- List of Raw Materials
- Properties of Raw Materials
- Prescribed Quality of Raw Materials
- List of Suppliers and Manufacturers
Personnel (Manpower) Requirements
- Requirement of Staff & Labor (Skilled and Unskilled) Managerial, Technical, Office Staff and Marketing Personnel
Plant and Machinery
- List of Plant & Machinery
- Miscellaneous Items
- Appliances &Equipments
- Laboratory Equipments& Accessories
- Electrification
- Electric Load & Water
- Maintenance Cost
- Sources of Plant & Machinery (Suppliers and Manufacturers)
Manufacturing Process and Formulations
- Detailed Process of Manufacture with Formulation
- Packaging Required
- Process Flow Sheet Diagram
Infrastructure and Utilities
- Project Location
- Requirement of Land Area
- Rates of the Land
- Built Up Area
- Construction Schedule
- Plant Layout and Requirement of Utilities
- Assumptions for Profitability workings
- Plant Economics
- Production Schedule
-
- Land & Building
- Factory Land & Building
- Site Development Expenses
-
- Plant & Machinery
- Indigenous Machineries
- Other Machineries (Miscellaneous, Laboratory etc.)
-
- Other Fixed Assets
- Furniture & Fixtures
- Pre-operative and Preliminary Expenses
- Technical Knowhow
- Provision of Contingencies
-
- Working Capital Requirement Per Month
- Raw Material
- Packing Material
- Lab & ETP Chemical Cost
- Consumable Store
-
- Overheads Required Per Month And Per Annum
- Utilities & Overheads (Power, Water and Fuel Expenses etc.)
- Royalty and Other Charges
- Selling and Distribution Expenses
- Salary and Wages
- Turnover Per Annum
-
- Share Capital
- Equity Capital
- Preference Share Capital
- Annexure 1:: Cost of Project and Means of Finance
-
- Annexure 2:: Profitability and Net Cash Accruals
- Revenue/Income/Realisation
- Expenses/Cost of Products/Services/Items
- Gross Profit
- Financial Charges
- Total Cost of Sales
- Net Profit After Taxes
- Net Cash Accruals
-
- Annexure 3 :: Assessment of Working Capital requirements
- Current Assets
- Gross Working. Capital
- Current Liabilities
- Net Working Capital
- Working Note for Calculation of Work-in-process
- Annexure 4 :: Sources and Disposition of Funds
-
- Annexure 5 :: Projected Balance Sheets
- ROI (Average of Fixed Assets)
- RONW (Average of Share Capital)
- ROI (Average of Total Assets)
-
- Annexure 6 :: Profitability ratios
- D.S.C.R
- Earnings Per Share (EPS)
- Debt Equity Ratio
-
- Annexure 7 :: Break-Even Analysis
- Variable Cost & Expenses
- Semi-Var./Semi-Fixed Exp.
- Profit Volume Ratio (PVR)
- Fixed Expenses / Cost
- B.E.P
-
- Annexure 8 to 11:: Sensitivity Analysis-Price/Volume
- Resultant N.P.B.T
- Resultant D.S.C.R
- Resultant PV Ratio
- Resultant DER
- Resultant ROI
- Resultant BEP
-
- Annexure 12 :: Shareholding Pattern and Stake Status
- Equity Capital
- Preference Share Capital
-
- Annexure 13 :: Quantitative Details-Output/Sales/Stocks
- Determined Capacity P.A of Products/Services
- Achievable Efficiency/Yield % of Products/Services/Items
- Net Usable Load/Capacity of Products/Services/Items
- Expected Sales/ Revenue/ Income of Products/ Services/ Items
- Annexure 14 :: Product wise domestic Sales Realisation
- Annexure 15 :: Total Raw Material Cost
- Annexure 16 :: Raw Material Cost per unit
- Annexure 17 :: Total Lab & ETP Chemical Cost
- Annexure 18 :: Consumables, Store etc.,
- Annexure 19 :: Packing Material Cost
- Annexure 20 :: Packing Material Cost Per Unit
- Annexure 21 :: Employees Expenses
- Annexure 22 :: Fuel Expenses
- Annexure 23 :: Power/Electricity Expenses
- Annexure 24 :: Royalty & Other Charges
- Annexure 25 :: Repairs & Maintenance Exp.
- Annexure 26 :: Other Mfg. Expenses
- Annexure 27 :: Administration Expenses
- Annexure 28 :: Selling Expenses
- Annexure 29 :: Depreciation Charges – as per Books (Total)
- Annexure 30 :: Depreciation Charges – as per Books (P & M)
- Annexure 31 :: Depreciation Charges - As per IT Act WDV (Total)
- Annexure 32 :: Depreciation Charges - As per IT Act WDV (P & M)
- Annexure 33 :: Interest and Repayment - Term Loans
- Annexure 34 :: Tax on Profits
- Annexure 35 ::Projected Pay-Back Period And IRR
- One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
- One Crore is equivalent to ten million (10,000,000)
- T.C.I is Total Capital Investment
- We can modify the project capacity and project cost as per your requirement.
- We can also prepare project report on any subject as per your requirement.
- Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.
Need assistance?
Share your details, we will call you
NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services.
Read more →Quick Links
Products & Services
Contact Info
| 106-E, Kamla Nagar,
New Delhi-110007, India. |
|
| +91 9097-075-054, +91-11-23843955, +91-11-23845886 Any quries? Call us. |
|
| [email protected]
Any quries? Mail Now. |
- Copyright © 2024 NPCS, All Right Reserved.
X
Have a business idea? Let’s make it
happen together-contact us now!